



B-Cell Directed Therapies for IgA Nephropathy

Draft Questions for Deliberation and Voting: February 26, 2026 Public Meeting

These questions are intended for the deliberation of the CTAF voting body at the public meeting.

Patient Population for all questions: *People with IgA Nephropathy (IgAN)*

Special Ethical Priorities

To help inform judgments of overall long-term value for money, please answer the following questions:

1=Typical obligations, 2=Some added obligations, 3=Substantial added obligations

1. Are there particular obligations to people with this condition because of disease severity and/or unmet need with currently available therapies?
2. Are there particular obligations to people with this condition because it disproportionately affects those from a racial/ethnic group that have not been equitably served by the healthcare system?
3. Apart from issues around disease severity/unmet need and race/ethnicity, are there other particular obligations to people with this condition?

Clinical Evidence

4. For patients with IgAN, is the current evidence adequate to demonstrate that the net health benefit of sibeprenlimab is greater than that of no specific immunomodulatory therapy?

Yes

No

5. For patients with IgAN, is the current evidence adequate to demonstrate that the net health benefit of atacicept is greater than that of no specific immunomodulatory therapy?

Yes

No

6. For patients with IgAN, is the current evidence adequate to demonstrate that the net health benefit of Nefecon is greater than that of no specific immunomodulatory therapy?

Yes

No

7. For patients with IgAN, is the current evidence adequate to demonstrate that the net health benefit of sibeprenlimab is greater than that of systemic glucocorticoids?

Yes

No

8. For patients with IgAN, is the current evidence adequate to demonstrate that the net health benefit of atacicept is greater than that of systemic glucocorticoids?

Yes

No

9. For patients with IgAN, is the current evidence adequate to demonstrate that the net health benefit of Nefecon is greater than that of systemic glucocorticoids?

Yes

No

10. Is the currently available evidence adequate to distinguish the net health benefit among sibeprenlimab, atacicept, and Nefecon?

Yes

No

If yes to question 10, answer questions 10a, 10b, and 10c...

10a. For patients with IgAN, which intervention has the greater net health benefit:

A. Sibeprenlimab

B. Atacicept

C. Can't distinguish

10b. For patients with IgAN, which intervention has the greater net health benefit:

A. Sibeprenlimab

B. Nefecon

C. Can't distinguish

10c. For patients with IgAN, which intervention has the greater net health benefit:

A. Atacicept

B. Nefecon

C. Can't distinguish

Benefits Beyond Health

To help inform judgments of overall long-term value for money, please answer the following questions about sibeprenlimab, atacicept, and Nefecon when compared to systemic glucocorticoids:

1=No; 2=Yes: small improvement; 3= Yes: substantial improvement

11. Is sibeprenlimab likely to improve caregivers' quality of life and/or ability to pursue their own education, work, and family life?
12. If payment/cost were not an issue, would sibeprenlimab be likely to improve access to treatment because of its method of delivery and/or treatment setting?
13. Is atacicept likely to improve caregivers' quality of life and/or ability to pursue their own education, work, and family life?
14. If payment/cost were not an issue, would atacicept be likely to improve access to treatment because of its method of delivery and/or treatment setting?
15. Is Nefecon likely to improve caregivers' quality of life and/or ability to pursue their own education, work, and family life?
16. If payment/cost were not an issue, would Nefecon be likely to improve access to treatment because of its method of delivery and/or treatment setting?
17. Other: as determined pre-meeting by ICER team based on input from patients, clinical experts, and appraisal committee members

Long-Term Value for Money

18. Given the available evidence on comparative clinical effectiveness and incremental cost effectiveness, and considering benefits beyond health and special ethical priorities, what is the long-term value for money of sibeprenlimab at current pricing?
 - a. High long-term value for money at current pricing
 - b. Intermediate long-term value for money at current pricing
 - c. Low long-term value for money at current pricing

19. Given the available evidence on comparative clinical effectiveness and incremental cost effectiveness, and considering benefits beyond health and special ethical priorities, what is the long-term value for money of Nefecon at current pricing?
- a. High long-term value for money at current pricing
 - b. Intermediate long-term value for money at current pricing
 - c. Low long-term value for money at current pricing
20. Given the available evidence on comparative clinical effectiveness and incremental cost effectiveness, and considering benefits beyond health and special ethical priorities, what is the long-term value for money of atacicept at assumed pricing?*
- a. High long-term value for money at assumed pricing
 - b. Intermediate long-term value for money at assumed pricing
 - c. Low long-term value for money at assumed pricing

**This vote will only be taken if a price becomes available for atacicept*